Zobrazeno 1 - 10
of 1 381
pro vyhledávání: '"rucaparib"'
Publikováno v:
Taiwanese Journal of Obstetrics & Gynecology, Vol 63, Iss 5, Pp 601-609 (2024)
Ovarian cancer stands as the third most prevalent gynecological malignancy. The advent of PARP inhibitors, particularly rucaparib, has revolutionized the landscape of advanced ovarian cancer treatment, demonstrating notable efficacy with minimal toxi
Externí odkaz:
https://doaj.org/article/a1cf2c54a9ac4fc898e1bff0fe8f2999
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Guojuan Sun, Yi Liu
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe landscape of poly (ADP-ribose) polymerase (PARP) inhibitor treatment for ovarian cancer (OC) is continually evolving. This research aimed to evaluate the efficacy and safety of PARP inhibitors compared to placebo as a maintenance therap
Externí odkaz:
https://doaj.org/article/32bbe5b73da74d1994c43187a85a90a8
Autor:
Pio Maiorano, Mauro Francesco a, Loizzi, Vera a, b, Maiorano, Brigida Anna c, ⁎, 1, Cormio, Gennaro a, b, 1
Publikováno v:
In European Journal of Obstetrics & Gynecology and Reproductive Biology February 2025 305:232-240
Autor:
Fangyi Yao, Fangmin Zhong, Junyao Jiang, Ying Cheng, Shuai Xu, Jing Liu, Jin Lin, Jing Zhang, Shuqi Li, Meiyong Li, Yanmei Xu, Bo Huang, Xiaozhong Wang
Publikováno v:
Genes and Diseases, Vol 11, Iss 2, Pp 993-1008 (2024)
Chronic myeloid leukemia (CML) is a common adult leukemia. Both the acute phase of the disease and the adverse effects of anti-cancer treatments can lead to a poor prognosis. The N6-methyladenine (m6A) modification plays an important regulatory role
Externí odkaz:
https://doaj.org/article/18be7aab6c184f62b6059464a67e75b0
Autor:
István Baradács, Brigitta Teutsch, Alex Váradi, Alexandra Bilá, Ádám Vincze, Péter Hegyi, Tamás Fazekas, Balázs Komoróczy, Péter Nyirády, Nándor Ács, Ferenc Bánhidy, Balázs Lintner
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-14 (2024)
Abstract Background Ovarian cancer is the eighth leading cause of cancer-related death among women, characterized by late diagnosis and a high relapse rate. In randomized controlled trials, we aimed to evaluate the efficacy and safety of PARP inhibit
Externí odkaz:
https://doaj.org/article/61e923472eb845c2937e2fb723ecf0d2
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was
Externí odkaz:
https://doaj.org/article/3bc485944c9442a5b5110520595877ef
Publikováno v:
Molecules, Vol 29, Iss 13, p 3073 (2024)
The microbiome is capable of modulating the bioavailability of chemotherapy drugs, mainly due to metabolizing these agents. Multiple cytostatic bacterial metabolites were recently identified that have cytostatic effects on cancer cells. In this study
Externí odkaz:
https://doaj.org/article/009a292c9f084314a8dfb56844a71dd1
Autor:
Jiang Yu, Wenfeng Gou, Haihua Shang, Yating Cui, Xiao Sun, Lingling Luo, Wenbin Hou, Tiemin Sun, Yiliang Li
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 952-972 (2022)
The poly (ADP-ribose) polymerase (PARP) inhibitors play a crucial role in cancer therapy. However, most approved PARP inhibitors cannot cross the blood-brain barrier, thus limiting their application in the central nervous system. Here, 55 benzodiazep
Externí odkaz:
https://doaj.org/article/b263a5cf0d02430aa54e1d1ed749ebc1
Autor:
Alfonso Yubero, Aranzazu Barquín, Purificación Estévez, Bella Pajares, Luisa Sánchez, Piedad Reche, Jesús Alarcón, Julia Calzas, Lydia Gaba, José Fuentes, Ana Santaballa, Carmen Salvador, Luis Manso, Ana Herrero, Álvaro Taus, Raúl Márquez, Julia Madani, María Merino, Gloria Marquina, Victoria Casado, Manuel Constenla, María Gutiérrez, Alba Dosil, Antonio González-Martín
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access
Externí odkaz:
https://doaj.org/article/535064772afa48388b62acdd5418de2a